Richard I. Steinhart
Mr. Steinhart brings significant financial and strategic experience in the biotechnology and medical device industries. Prior to joining BioXcel Therapeutics, Richard served as Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. Prior to joining Remedy Pharmaceuticals, Mr. Steinhart served as an independent consultant to biotechnology and medical device companies. Previously, he was the Senior Vice President, Finance and Chief Financial Officer of MELA Sciences. Prior to joining MELA Sciences, Mr. Steinhart held a variety of senior-level positions at Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies, Emisphere Technologies, Inc., and CW Group, Inc., a venture capital firm focused on medical technology. He began his career at PriceWaterhouseCoopers.
Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc. and Atossa Genetics, Inc. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).